IL17A and systemic sclerosis: As expected, treatment with IL-17A neutralizing antibodies reduced the detection of IL-17A in the supernatant cell cultures (13.77±6.04 vs 150.85±57.4 pg/ml in healthy subjects, p<0.001; 226.43±94.03 vs 464.54±139.5 pg/ml in SSc patients, p<0.001) whereas it did not affect IL-17A mRNA expression (relative mRNA levels 0.9- fold in healthy subjects; from 2.5-fold to 2.38-fold in SSc compared to control).